News + Font Resize -

Roche announces final results of tender offer for Foundation Medicine
Basel | Tuesday, April 14, 2015, 16:00 Hrs  [IST]

Roche announced the final results of the tender offer by Roche Holdings, Inc., its wholly owned subsidiary, to purchase up to 15,604,288 shares of common stock of Foundation Medicine, Inc. at USD 50.00 per share in cash, which expired at 12:00 midnight, New York City time, at the end of the day on 6 April 2015.

The shares purchased by Roche in the tender offer, when added to the shares already owned by Roche and its affiliates (including 5,000,000 shares issued by FMI to Roche on 7 April 2015), total approximately 21,019,111 shares, representing approximately 57% of the outstanding shares of FMI’s common stock on a fully diluted basis as of 7 April 2015.

Based on the final tabulation by Citibank, N.A., the depositary for the tender offer, a total of 18,758,256 shares of FMI’s common stock were validly tendered and not validly withdrawn in the tender offer. Because the tender offer was oversubscribed, the number of shares accepted for purchase by Roche from each of the tendering stockholders has been prorated. The final proration factor is 83.186197%.

Payment for shares accepted for purchase by Roche will be made promptly in accordance with the terms of the tender offer. All shares tendered in the tender offer but not accepted for purchase will be returned to the tendering stockholders.

In connection with the closing of the previously announced strategic collaboration, FMI’s board of directors now includes Daniel O'Day, Roche Pharmaceuticals Division, chief operating officer and member of the Roche corporate executive committee, Sandra J. Horning, M.D., global head, product development and chief medical officer for Roche/Genentech, and Michael D. Varney, Ph.D., head, Genentech Research and Early Development, and the previously announced research and development and commercial collaborations between the parties became effective.

Post Your Comment

 

Enquiry Form